

**Summary of Consolidated Financial Results for
the First Quarter of the Fiscal Year Ending March 31, 2026
(Three Months Ended June 30, 2025)**

[Japanese GAAP]

Company name: NIHON TRIM CO., LTD. Listing: Tokyo Stock Exchange
 Securities code: 6788 URL: <https://www.nihon-trim.co.jp/>
 Representative: Norio Tahara, President
 Contact: Yasuhiro Daikoku, Senior Managing Executive Officer and General Manager of Administration
 Division
 Tel: +81-(0) 6-6456-4600
 Scheduled date of dividend payment: –
 Supplementary materials for financial results: Yes
 Holding of financial results meeting: None

(All amounts are rounded down to the nearest million yen)

1. Consolidated Financial Results for the Three Months Ended June 30, 2025 (April 1, 2025 - June 30, 2025)

(1) Consolidated results of operations (Percentages represent year-on-year changes)

| | Net sales | | Operating profit | | Ordinary profit | | Profit attributable to owners of parent | |
|----------------------------------|-------------|------|------------------|--------|-----------------|--------|---|--------|
| | Million yen | % | Million yen | % | Million yen | % | Million yen | % |
| Three months ended June 30, 2025 | 5,949 | 9.0 | 576 | (25.4) | 627 | (22.9) | 401 | (29.4) |
| Three months ended June 30, 2024 | 5,459 | 13.8 | 772 | 39.2 | 814 | 37.5 | 568 | 33.7 |

Note: Comprehensive income (million yen) Three months ended June 30, 2025: 306 (down 50.8%)

Three months ended June 30, 2024: 623 (up 30.1%)

| | Net income per share | Diluted net income per share |
|----------------------------------|----------------------|------------------------------|
| | Yen | Yen |
| Three months ended June 30, 2025 | 52.40 | – |
| Three months ended June 30, 2024 | 74.18 | – |

(2) Consolidated financial position

| | Total assets | Net assets | Equity ratio | Net assets per share |
|---------------------|--------------|-------------|--------------|----------------------|
| | Million yen | Million yen | % | Yen |
| As of Jun. 30, 2025 | 34,806 | 24,546 | 66.1 | 3,020.09 |
| As of Mar. 31, 2025 | 35,353 | 25,546 | 67.8 | 3,125.80 |

Reference: Shareholders' equity (million yen) As of Jun. 30, 2025: 23,004 As of Mar. 31, 2025: 23,967

2. Dividends

| | Dividend per share | | | | |
|--|--------------------|--------------------|-------------------|-----------------|--------|
| | First quarter-end | Second quarter-end | Third quarter-end | Fiscal year-end | Total |
| | Yen | Yen | Yen | Yen | Yen |
| Fiscal year ended Mar. 31, 2025 | – | 0.00 | – | 130.00 | 130.00 |
| Fiscal year ending Mar. 31, 2026 | – | | | | |
| Fiscal year ending Mar. 31, 2026 (forecasts) | | 0.00 | – | 130.00 | 130.00 |

Note: Revisions to the most recently announced dividend forecast: None

3. Consolidated Forecast for the Fiscal Year Ending March 31, 2026 (April 1, 2025 - March 31, 2026)

(Percentages represent year-on-year changes)

| | Net sales | | Operating profit | | Ordinary profit | | Profit attributable to owners of parent | | Net income per share |
|------------|-------------|------|------------------|-------|-----------------|-------|---|-------|----------------------|
| | Million yen | % | Million yen | % | Million yen | % | Million yen | % | Yen |
| First half | 12,500 | 10.0 | 1,750 | (5.7) | 1,830 | (6.1) | 1,180 | (9.7) | 156.35 |
| Full year | 25,000 | 11.3 | 3,540 | 7.7 | 3,700 | 4.7 | 2,300 | 2.6 | 304.74 |

Note: Revisions to the most recently announced consolidated forecast: None

*** Notes**

(1) Significant changes in the scope of consolidation during the period: None

Newly added: –

Excluded: –

(2) Application of special accounting methods for presenting quarterly consolidated financial statements: None

(3) Changes in accounting policies and accounting estimates, and restatements

(i) Changes in accounting policies due to revisions in accounting standards, others: None

(ii) Changes in accounting policies other than (i) above: None

(iii) Changes in accounting estimates: None

(iv) Restatements: None

(4) Number of outstanding shares (common shares)

(i) Number of shares issued at end of period (including treasury shares)

As of Jun. 30, 2025: 8,656,780 shares

As of Mar. 31, 2025: 8,656,780 shares

(ii) Number of treasury shares at end of period

As of Jun. 30, 2025: 1,039,456 shares

As of Mar. 31, 2025: 989,256 shares

(iii) Average number of shares outstanding during the period

Three months ended Jun. 30, 2025: 7,656,081 shares

Three months ended Jun. 30, 2024: 7,665,020 shares

Note: The Company has adopted the Employee Stock Ownership Plan (J-ESOP) and the Trust-Type Employee Shareholding Incentive Plan (E-Ship). The company shares held by these trusts are included in the number of treasury shares, which are to be deducted from the calculation of the number of treasury shares at end of period and the average number of shares outstanding during the period.

* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

* Cautionary statement with respect to forward-looking statements, and other special items

Earnings forecasts regarding future performance in this material are based on assumptions judged to be valid and information currently available to the Company, and the Company does not in any way guarantee the achievement of the forecasts. Actual results may differ significantly from these forecasts for a number of factors. Please refer to “1. Overview of Results of Operations, etc., (3) Explanation of the Future Outlook, including Consolidated Performance Forecasts” on page 4 of the attachments for assumptions for forecasts and notes of caution for usage.

Contents of Attachments

| | |
|---|----|
| 1. Overview of Results of Operations, etc. | 2 |
| (1) Overview of Results of Operations for the Period under Review | 2 |
| (2) Overview of Financial Position for the Period under Review | 3 |
| (3) Explanation of the Future Outlook, including Consolidated Performance Forecasts | 4 |
| 2. Quarterly Consolidated Financial Statements and Notes | 5 |
| (1) Quarterly Consolidated Balance Sheet | 5 |
| (2) Quarterly Consolidated Statement of Income and Quarterly Consolidated Statement of Comprehensive Income | 7 |
| Quarterly Consolidated Statement of Income | 7 |
| Quarterly Consolidated Statement of Comprehensive Income | 8 |
| (3) Notes to Quarterly Consolidated Financial Statements | 9 |
| Segment and Other Information | 9 |
| Significant Changes in Shareholders' Equity | 9 |
| Assumption for Going Concern | 9 |
| Statement of Cash Flows | 10 |

1. Overview of Results of Operations, etc.

(1) Overview of Results of Operations for the Period under Review

The Nihon Trim Group (“the Group”) is committed to “contributing to the creation of healthy and comfortable lives” under its corporate philosophy. To this end, the Group operates its business under the main theme of health and medical care. The Group’s mission is to contribute to people’s well-being through its businesses including Electrolyzed Hydrogen Water (EHW), electrolyzed water hemodialysis, and regenerative medicine. The Group’s EHW apparatus is a controlled medical device that has been approved for its effects on improvement of gastrointestinal conditions, and its water purification cartridge is equipped with a function to remove PFAS (generic name for organic fluorine compounds) (*1), whose environmental impact has become a global issue in recent years, thereby contributing to the creation of an environment where people can live in good health with peace of mind. Under the slogan “Society will always need our products, at any point in time,” the Group will contribute to the realization of a sustainable society and achieve sustainable enhancement of its corporate and shareholder value.

(*1) Water purification capacity was tested using the method specified in voluntary standards of Japan Water Purifier Association (JWPAS B). We have confirmed that the removal rate of PFOS and PFOA, which are particularly harmful among PFAS, is 80% or higher for all types of our water purification cartridges (results of JWPAS B.210 test).

During the first three months of the current fiscal year, the Group’s net sales increased 9.0% year on year to 5,949 million yen, hitting a record quarterly high. However, operating profit decreased 25.4% to 576 million yen, ordinary profit decreased 22.9% to 627 million yen, and profit attributable to owners of parent decreased 29.4% to 401 million yen resulting in lower profits compared to the same period of the previous fiscal year. This is due to human resource investment for further business expansion, and an increase in advertising expenses for a bottled water business in Indonesia, which are already reflected in the initial plan, and the progress of the first three months of the current fiscal year is in accordance with the plan.

The Group is promoting a medium-term management plan targeting 31,000 million yen in consolidated net sales for the fiscal year ending March 31, 2028, and the current fiscal year is the first year of the plan. While driving the EHW apparatus sales business as our core business, we will also put our energy into the bottled water business, the electrolyzed water hemodialysis business, and the field of regenerative medicine, and thereby achieve the medium-term management plan, aiming to enhance its medium-to long-term corporate value.

Results by business segment were as follows.

Water Healthcare Business

In the EHW apparatus sales business, net sales increased 2.9% year on year to 2,366 million yen.

In the direct sales division, the development of new channels in the sports and beauty care fields, to which the DS Division, which primarily focuses on workplace sales, is committed, progressed favorably, with successful initiatives to enhance sales skills and capabilities. As a result, the number of ordered EHW apparatus reached a record high on a monthly basis in June 2025. The sales revenue of EHW apparatus is to be recorded after the completion of installation, and is therefore reflected in the sales results in and after July. We will continue to make efforts to improve sales efficiency and personnel increase.

In the wholesale and OEM division (MS Division), which covers indirect sales, net sales decreased 29.1% year on year, as a result of a slowdown in shipments to some existing agents. We have already taken action to strengthen sales support for agents, and net sales are expected to recover in the second quarter onward.

With regard to sales of water purification cartridges in Japan, which generate a consistent revenue stream once an EHW apparatus is installed, net sales increased 2.5% to 1,452 million yen, showing strong performance. We will continue to strengthen customer service, including regular information distribution and follow-up calls, aiming to maintain and expand a stable revenue base.

PT. SUPER WAHANA TEHNO, which operates a bottled water business in Indonesia, recorded net sales of

1,074 million yen (up 40.4% year on year). For the purpose of expanding market share, we plan to reinforce marketing measures during the current fiscal year more than in the previous fiscal year. Driven by a launched TV commercial campaign, as well as advertisements on social networking services and enhanced promotional activities, the business continues steadily growing. Although initial costs are required, we feel confident in the potential for significant growth in the next fiscal year onward. In parallel with sales expansion, we are discussing the new construction of our own factories. We will enable reinforced production capacity, aiming to improve management efficiency.

As a result of the above, the water healthcare business recorded net sales of 5,196 million yen (up 9.1% year on year), with segment profit of 548 million yen (down 20.5% year on year). The decrease in segment profit is due to the expansion of human resource investment, and the increase of advertising expenses in the bottled water business in Indonesia, as mentioned above, which have been reflected in the initial plan.

Medical Business

In the electrolyzed water hemodialysis (*2) business, as a result of new introduction at one facility in June 2025, the number of facilities that have adopted electrolyzed water hemodialysis has currently reached 35 facilities with 1,093 beds, and approximately 3,300 people are currently receiving treatments with electrolyzed water hemodialysis. At the 70th Annual Meeting of the Japanese Society for Dialysis Therapy held in June 2025, five titles related to electrolyzed water hemodialysis were presented. Among others, a luncheon seminar “New Possibilities of Electrolyzed Water Hemodialysis” was attended by more than 300 people in total, and recognition of electrolyzed water hemodialysis is steadily increasing. After the meeting, some facilities decided to purchase RO machines for individuals, and others requested estimates. Through setting up a booth at conferences related to hemodialysis and holding seminars, we will strive for the widespread use of electrolyzed water hemodialysis going forward.

(*2) Electrolyzed water hemodialysis offers a next-generation of new dialysis treatment using electrolyzed RO water containing dissolved hydrogen, which is produced by our technology, to dilute dialysate. It is unconventional technology that focuses attention on the functions of water as a solvent for the first time in the world. We obtained data that showed that electrolyzed water hemodialysis reduced the dosage of drugs and the complication rate and annual crude death rate (CDR) of patients compared to traditional hemodialysis, which has drawn attention.

In the field of regenerative medicine, StemCell Institute Inc. (listed on TSE Growth Market, Securities Code: 7096, our share: 70.6%) achieved a new record high in quarterly net sales. The company published its earnings results for the three months ended June 30, 2025, on August 7 this year, the same date as did the Group. For details, please refer to the StemCell Institute’s Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2026.

As a result of the above, the medical business recorded net sales of 753 million yen (up 8.5% year on year) with segment profit of 28 million yen (down 66.0% year on year). The decrease in segment profit is due to the expansion of human resource investment and the restructuring of the sales organization for StemCell Institute Inc., and expenses arising associated with the launch of business in Singapore, which have been reflected in the initial plan.

(2) Overview of Financial Position for the Period under Review

Total assets decreased 547 million yen, or 1.5%, from the end of the previous fiscal year to 34,806 million yen at the end of the first quarter of the current fiscal year on a consolidated basis. The main factor was a decrease in cash and deposits of 1,732 million yen, despite increases in investment securities of 707 million yen and notes and accounts receivable–trade of 472 million yen.

Total liabilities increased 451 million yen, or 4.6%, from the end of the previous fiscal year to 10,259 million yen. The main factors were increases in accounts payable–other of 304 million yen and deposits received of 121 million yen included in other under current liabilities, advances received of 116 million yen and accounts payable–trade of 105 million yen, despite decreases in income taxes payable of 256 million yen and provision for bonuses of 125 million yen.

Net assets decreased 999 million yen, or 3.9%, from the end of the previous fiscal year to 24,546 million yen. The main factors were dividend payments of 1,077 million yen, an increase in treasury shares of 205 million yen and a decrease in foreign currency translation adjustment of 69 million yen, which were partially offset by an increase due to the

recognition of profit attributable to owners of parent of 401 million yen.

(3) Explanation of the Future Outlook, including Consolidated Performance Forecasts

There are no revisions to the full-year consolidated forecast for the fiscal year ending March 31, 2026, which was announced in the “Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2025,” dated May 13, 2025.

2. Quarterly Consolidated Financial Statements and Notes**(1) Quarterly Consolidated Balance Sheet**

| | (Thousands of yen) | |
|--|---------------------------------|--|
| | FY3/25 (As of Mar. 31, 2025) | First quarter of FY3/26 (As of Jun. 30, 2025) |
| Assets | | |
| Current assets | | |
| Cash and deposits | 15,394,490 | 13,662,418 |
| Notes and accounts receivable-trade | 6,343,591 | 6,815,634 |
| Securities | 1,001,865 | 1,001,865 |
| Finished goods | 627,719 | 647,299 |
| Raw materials and supplies | 1,104,771 | 1,030,554 |
| Other | 304,347 | 307,861 |
| Allowance for doubtful accounts | (26,437) | (27,051) |
| Total current assets | 24,750,348 | 23,438,582 |
| Non-current assets | | |
| Property, plant and equipment | | |
| Land | 2,983,117 | 2,979,695 |
| Other, net | 2,004,225 | 1,950,623 |
| Total property, plant and equipment | 4,987,342 | 4,930,318 |
| Intangible assets | | |
| Goodwill | 311,791 | 302,511 |
| Other | 318,356 | 317,698 |
| Total intangible assets | 630,147 | 620,209 |
| Investments and other assets | | |
| Investment securities | 1,306,584 | 2,013,674 |
| Long-term time deposits | 1,500,000 | 1,500,000 |
| Other | 2,228,856 | 2,353,224 |
| Allowance for doubtful accounts | (49,500) | (49,500) |
| Total investments and other assets | 4,985,940 | 5,817,398 |
| Total non-current assets | 10,603,431 | 11,367,926 |
| Total assets | 35,353,779 | 34,806,508 |
| Liabilities | | |
| Current liabilities | | |
| Accounts payable-trade | 589,774 | 694,838 |
| Income taxes payable | 532,132 | 275,341 |
| Advances received | 4,072,488 | 4,188,853 |
| Provision for bonuses | 200,425 | 75,080 |
| Provision for product warranties | 85,000 | 90,000 |
| Other | 1,675,210 | 2,184,098 |
| Total current liabilities | 7,155,031 | 7,508,212 |
| Non-current liabilities | | |
| Long-term borrowings | 1,131,089 | 1,115,747 |
| Provision for share-based payments | 177,454 | 200,261 |
| Provision for retirement benefits for directors (and other officers) | 260,406 | 270,289 |
| Retirement benefit liability | 367,842 | 375,592 |
| Other | 715,786 | 789,459 |
| Total non-current liabilities | 2,652,578 | 2,751,349 |
| Total liabilities | 9,807,610 | 10,259,561 |

| | (Thousands of yen) | |
|---|-----------------------|-------------------------|
| | FY3/25 | First quarter of FY3/26 |
| | (As of Mar. 31, 2025) | (As of Jun. 30, 2025) |
| Net assets | | |
| Shareholders' equity | | |
| Share capital | 992,597 | 992,597 |
| Capital surplus | 1,864,182 | 1,852,072 |
| Retained earnings | 24,391,935 | 23,715,767 |
| Treasury shares | (3,408,285) | (3,614,099) |
| Total shareholders' equity | 23,840,429 | 22,946,338 |
| Accumulated other comprehensive income | | |
| Valuation difference on available-for-sale securities | (14,881) | (9,850) |
| Foreign currency translation adjustment | 108,612 | 38,749 |
| Remeasurements of defined benefit plans | 33,004 | 29,740 |
| Total accumulated other comprehensive income | 126,735 | 58,638 |
| Non-controlling interests | 1,579,004 | 1,541,969 |
| Total net assets | 25,546,169 | 24,546,946 |
| Total liabilities and net assets | 35,353,779 | 34,806,508 |

(2) Quarterly Consolidated Statement of Income and Quarterly Consolidated Statement of Comprehensive Income**Quarterly Consolidated Statement of Income
(For the Three-month Period)**

| | (Thousands of yen) | |
|---|---|---|
| | First three months of FY3/25 (Apr. 1, 2024 - June. 30, 2024) | First three months of FY3/26 (Apr. 1, 2025 - June. 30, 2025) |
| Net sales | 5,459,216 | 5,949,878 |
| Cost of sales | 1,636,913 | 1,905,168 |
| Gross profit | 3,822,303 | 4,044,709 |
| Selling, general and administrative expenses | 3,050,157 | 3,468,315 |
| Operating profit | 772,145 | 576,394 |
| Non-operating income | | |
| Interest and dividend income | 12,856 | 23,703 |
| Share of profit of entities accounted for using equity method | 1,374 | — |
| Rental income from real estate | 21,004 | 21,004 |
| Foreign exchange gains | 362 | — |
| Gain on sale of non-current assets | 9,710 | 7,761 |
| Other | 2,249 | 7,162 |
| Total non-operating income | 47,556 | 59,631 |
| Non-operating expenses | | |
| Interest expenses | 286 | 1,358 |
| Share of loss of entities accounted for using equity method | — | 664 |
| Depreciation of assets for rent | 3,664 | 3,485 |
| Foreign exchange losses | — | 24 |
| Provision of allowance for doubtful accounts | 300 | — |
| Other | 1,099 | 2,811 |
| Total non-operating expenses | 5,351 | 8,344 |
| Ordinary profit | 814,351 | 627,681 |
| Extraordinary income | | |
| Gain on sale of non-current assets | — | 487 |
| Gain on sale of investment securities | 149,274 | — |
| Total extraordinary income | 149,274 | 487 |
| Profit before income taxes | 963,625 | 628,169 |
| Income taxes-current | 237,587 | 220,136 |
| Income taxes-deferred | 62,343 | (19,476) |
| Total income taxes | 299,930 | 200,659 |
| Profit | 663,694 | 427,509 |
| Profit attributable to non-controlling interests | 95,123 | 26,299 |
| Profit attributable to owners of parent | 568,571 | 401,210 |

Quarterly Consolidated Statement of Comprehensive Income
(For the Three-month Period)

| | (Thousands of yen) | |
|--|---|---|
| | First three months of FY3/25 (Apr. 1, 2024 - June. 30, 2024) | First three months of FY3/26 (Apr. 1, 2025 - June. 30, 2025) |
| Profit | 663,694 | 427,509 |
| Other comprehensive income | | |
| Valuation difference on available-for-sale securities | (103,348) | 6,684 |
| Foreign currency translation adjustment | 61,944 | (122,953) |
| Remeasurements of defined benefit plans, net of tax | 586 | (3,795) |
| Share of other comprehensive income of entities accounted for using equity method | 358 | (1,036) |
| Total other comprehensive income | (40,457) | (121,102) |
| Comprehensive income | 623,236 | 306,407 |
| Comprehensive income attributable to: | | |
| Owners of parent | 531,714 | 332,797 |
| Non-controlling interests | 91,522 | (26,389) |

(3) Notes to Quarterly Consolidated Financial Statements**Segment and Other Information****1. Overview of reportable segment**

The Group's reportable segment is a component for which discrete financial information is available and which is regularly reviewed by the Group's highest decision-making body in order to determine management resources to be allocated to the segment and assess its performance.

There are two reportable operating segments: the water healthcare business and the medical business.

The water healthcare business includes EHW apparatus sales and associated operations. The medical business includes business operations in the fields of medical and preventive healthcare and regenerative medicine.

2. Information related to net sales and profit or loss of each reportable segment**I. First three months of FY3/25 (Apr. 1, 2024 - Jun. 30, 2024)**

(Thousands of yen)

| | Reportable segment | | | Adjustments | Amounts recorded in quarterly consolidated financial statement of income (Note) |
|---------------------------------------|--------------------|---------|-----------|-------------|---|
| | Water Healthcare | Medical | Subtotal | | |
| Net sales | | | | | |
| Net sales to external customers | 4,765,007 | 694,208 | 5,459,216 | — | 5,459,216 |
| Inter-segment net sales and transfers | — | — | — | — | — |
| Total | 4,765,007 | 694,208 | 5,459,216 | — | 5,459,216 |
| Segment profit | 689,423 | 82,722 | 772,145 | — | 772,145 |

Note: The segment profit subtotal is consistent with the operating profit of the quarterly consolidated statement of income.

II. First three months of FY3/26 (Apr. 1, 2025 - Jun. 30, 2025)

(Thousands of yen)

| | Reportable segment | | | Adjustments | Amounts recorded in quarterly consolidated financial statement of income (Note) |
|---------------------------------------|--------------------|---------|-----------|-------------|---|
| | Water Healthcare | Medical | Subtotal | | |
| Net sales | | | | | |
| Net sales to external customers | 5,196,829 | 753,049 | 5,949,878 | — | 5,949,878 |
| Inter-segment net sales and transfers | — | — | — | — | — |
| Total | 5,196,829 | 753,049 | 5,949,878 | — | 5,949,878 |
| Segment profit | 548,269 | 28,125 | 576,394 | — | 576,394 |

Note: The segment profit subtotal is consistent with the operating profit of the quarterly consolidated statement of income.

Significant Changes in Shareholders' Equity

Not applicable.

Assumption for Going Concern

Not applicable.

Statement of Cash Flows

Quarterly consolidated statement of cash flows for the first three months of the current fiscal year have not been prepared. Depreciation (including depreciation related to intangible assets excluding goodwill) and amortization of goodwill for the first three months of the current fiscal year are as follows.

| | First three months of FY3/25 (Apr. 1, 2024 - Jun. 30, 2024) | First three months of FY3/26 (Apr. 1, 2025 - Jun. 30, 2025) |
|--------------------------|--|--|
| Depreciation | 73,243 thousand yen | 73,101 thousand yen |
| Amortization of goodwill | 9,279 thousand yen | 9,279 thousand yen |

This financial report is solely a translation of “Kessan Tanshin” (in Japanese, including attachments), which has been prepared in accordance with accounting principles and practices generally accepted in Japan, for the convenience of readers who prefer an English translation.